Overview

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. Coherus's mission is to improve patient lives by expanding access to these essential treatments, helping to offset rising healthcare costs. The company serves healthcare providers, hospitals, and patients, focusing on rigorous research and development to ensure their products meet high quality and efficacy standards. By providing cost-effective alternatives to original biologics, Coherus creates a competitive advantage in the biopharmaceutical market, driving sales and profitability while enhancing healthcare accessibility.

Simplify's Take

What believers are saying

• Increased focus on immuno-oncology enhances pipeline and market position.
• Launch of Udenyca wearable injector device improves drug delivery systems.
• Strategic collaborations could lead to new partnerships and investment opportunities.

What critics are saying

• Exit from biosimilar space may lead to loss of market share.
• 30% staff reduction could affect innovation and productivity.
• Collaboration with Cancer Research Institute may face scientific and regulatory hurdles.

What makes Coherus BioSciences unique

• Focus on biologic therapeutics for oncology and inflammatory diseases.
• Expertise in process science and analytical characterization.
• Commitment to high-quality, cost-effective biosimilars.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Stock Price